Release Summary

Ab Initio Biotherapeutics, Inc., today announced a collaborative research and license agreement with Pfizer Inc. (NYSE: PFE) to discover novel therapeutic antibodies against an undisclosed GPCR target

Ab Initio Biotherapeutics, Inc.